EUCTR2011-000038-12-GB进行中（未招募）不适用
A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy. - Trimetazidine therapy in hypertrophic cardiomyopathy
niversity College London (UCL)0 个研究点开始时间: 2011年8月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Non-obstructive hypertrophic cardiomyopathy (gradient < 50 mmHg)
- •NYHA Class = 2
- •Abnormal peak VO2 as % predicted for age and gender
- •Age 18 years or above
- •Resting heart rate < 90/minute at rest. Rhythm may be sinus rhythm (SR), atrial fibrillation (AF) or paced.
- •No significant renal or hepatic impairment
- •Able to comply with study requirements and able to give informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Female participant who is pregnant, breast-feeding or planning pregnancy during the course of the study. Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for trial treatment.
- •Significant renal (GFR <60ml/min) or hepatic impairment
- •Involvement in another research study in the past 12 weeks
- •Diabetes mellitus
- •Known hypersensitivity to trimetazidine
- •Participant has Parkinson’s disease or Parkinsonism.
研究者
相似试验
进行中（未招募）
不适用
A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury - BRAIN trialEUCTR2006-002813-11-ESXytis Pharmaceuticals Sàrl400
进行中（未招募）
不适用
A study to evaluate the efficacy, safety and tolerability of CT327 ointment in subjects with mild/moderate atopic dermatitisEUCTR2012-005389-36-GBCreabilis Limited210
进行中（未招募）
不适用
A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury - BRAIN trialEUCTR2006-002813-11-GBXytis Pharmaceuticals Sàrl400
进行中（未招募）
1 期
A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury - BRAIN trialModerate to Severe Traumatic Brain InjuryMedDRA version: 8.1Level: LLTClassification code 10060690Term: Traumatic brain injuryEUCTR2006-002813-11-BEXytis Pharmaceuticals Sàrl400
进行中（未招募）
不适用
A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury - BRAIN trialModerate to Severe Traumatic Brain InjuryMedDRA version: 8.1Level: LLTClassification code 10060690Term: Traumatic brain injuryEUCTR2006-002813-11-CZXytis Pharmaceuticals Sàrl400